Novartis drops PhII Parkinson's program
This article was originally published in Scrip
Novartis has discontinued development of the investigative compound AFQ056 to treat the jerky motions and tics that are a side-effect of treatment with levodopa in patients with Parkinson's disease. The firm had been planning to file its first regulatory approval submissions in this indication in 2015. However, the product failed to show efficacy in Parkinson's disease levodopa-induced dyskinesia (PD-LID) in recent Phase II studies.
You may also be interested in...
Geneva, Switzerland-based Addex Therapeutics has raised CHF40m to pursue its novel negative allosteric modulator in a late-stage study for levodopa-induced dyskinesia associated with Parkinson's disease.
The US FDA approved the extended-release amantadine for levodopa-induced dyskinesia in Parkinson's disease. Adamas will finalize its pricing and begin selling the product later this year.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.